Is QMS Medical overvalued or undervalued?

As of 14 August 2025, the valuation grade for QMS Medical has moved from very attractive to attractive. The company is currently assessed as undervalued, with a price-to-earnings (PE) ratio of 12.74, an EV to EBITDA ratio of 8.31, and a PEG ratio of 0.64. In comparison to its peers, QMS Medical stands out with a significantly lower PE ratio than Poly Medicure, which is at 53.86, and Blue Jet Health, which has a PE of 38.33, both categorized as very expensive.
Despite the recent decline in stock performance, with a year-to-date return of -33.85% compared to a 4.17% increase in the Sensex, QMS Medical's financial metrics suggest it remains a compelling investment opportunity within the healthcare services industry. The company's solid ROCE of 13.06% and ROE of 12.84% further reinforce its potential for value creation, indicating that it may be undervalued relative to its peers.